课题基金 / 基金详情

SARS CoV-2 Nsp1 inhibitor

SARS CoV-2 Nsp1 inhibitor
SARS CoV-2 Nsp1 抑制剂
批准号：
10263809
负责人：
James Inglese
金额：
$22.11万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10263809
关键词：
2019-nCoVAntiviral AgentsAttenuatedBindingBiological AssayBiophysicsCell LineCellsCollaborationsColoradoGene ExpressionGenetic TranscriptionGenomicsIn VitroInterferonsLaboratoriesMutationProteinsRecombinantsReporterRibosomesSeriesSevere Acute Respiratory SyndromeSignal TransductionStructureSystemTokyoTranslationsUniversitiesValidationViral Nonstructural ProteinsVirulence FactorsVirusbasedesigninhibitor/antagonistinterestmedical schoolsresponsescreeningsite-specific integrationvaccine trialvirology

项目摘要

项目成果

James Inglese的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
qHTS assays have been developed using several strategies. The first, uses an in vitro transcription and translation system to directly assess the functional effect of nsp1 on ribosomal translation. The second encompass cell-based assays conditionally expressing the nsp1 protein in different formats, including a coincidence reporter cell lines previously designed to allow a site-specific integration of any protein of interest, here SARS-CoV2 Nsp1 into a genomic background containing an inducible coincidence reporter system. Finally, direct biophysical assessment of candidate compound binding to nsp1 will be verified with a SPR-based assay using recombinant biotinylated nsp1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Juvenile Myositis
Juvenile Myositis
Juvenile Myositis
Charcot-Marie-Tooth (CMT) Disease
海外基金